|
Phase 2 Trials
|
Retrospective series
|
|---|
|
Treatment
|
Lapatinib [12]
|
Sorafenib [13]
|
Imatinib [10]
|
French Sarcoma Group [15]
|
Imatinib [11]
|
Pazopanib and sunitinib [16]
|
|---|
|
Number of cases
|
18
|
27
|
56
|
80
|
48
|
5
|
|
PFS (months)
|
8.2
|
NR
|
9
|
9.4
|
9.9
|
14
|
|
OS (months)
|
25
|
NR*
|
34.5
|
52.8
|
30
|
-
|
|
BORR (%)
|
0
|
3.7
|
2
|
6
|
0
|
20 (one patient)
|
- BORR best objective response rate, NR not reached but > 15 months, OS median overall survival, PFS median progression-free survival, * 12 months OS rate 86.5%
Journal of Medical Case Reports